Lista de obras - Alessandro Pancrazzi - Dominio Público Uruguay

A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF- 1 in the development of myelofibrosis

article

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

artículo científico publicado en 2008

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis

artículo científico publicado en 2005

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

artículo científico publicado en 2013

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

artículo científico publicado en 2007

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

artículo científico publicado en 2007

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

artículo científico publicado en 2014

CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin

artículo científico publicado en 2010

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

artículo científico publicado en 2017

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

artículo científico publicado en 2016

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

artículo científico publicado en 2013

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

artículo científico publicado en 2010

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.

artículo científico publicado en 2006

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

artículo científico publicado en 2009

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

artículo científico publicado en 2015

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

artículo científico publicado en 2013

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

artículo científico publicado en 2006

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

artículo científico

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

artículo científico publicado en 2010

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

artículo científico publicado en 2008

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

artículo científico publicado en 2004

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

artículo científico publicado en 2015

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

artículo científico publicado en 2007

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

artículo científico publicado en 2006

Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization

artículo científico publicado en 2014

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

artículo científico publicado en 2017

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

artículo científico publicado en 2016

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

artículo científico publicado en 2017

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

artículo científico publicado en 2011

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

artículo científico publicado en 2012

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

artículo científico publicado en 2013

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

scientific article published on 19 February 2014

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

artículo científico publicado en 2015

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds

artículo científico publicado en 2005

WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential.

artículo científico publicado en 2005

Lista de obras de Alessandro Pancrazzi

A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF- 1 in the development of myelofibrosis

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds

WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential.